Vienna to Host BIO-Europe 2009
First time that the largest stand-alone
partnering event is held outside of Germany
Zurich, Switzerland; Carlsbad,
USA; Vienna, Austria, November 20, 2008 – At the
closing of BIO-Europe 2008 in Mannheim/Heidelberg which
saw 2400 life science executives engage in an astounding
10,250 one-to-one meetings, EBD Group today announced that
next year’s BIO-Europe partnering conference will pay a
visit to Vienna, Austria. The 15th annual edition of BIO-Europe,
the world’s largest stand-alone partnering event will gather
leaders of the life science industry at the Wiener Messe
on Nov. 2–4, 2009 to take dealmaking to a new level. This
represents the first time in the conference’s 14 year history
that it will venture outside of Germany, and is testimony
to the recognition of the Vienna region’s emergence as a
robust cluster of biotech innovation.
Joining LISA VR in welcoming BIO-Europe 2009 will be the
Ministry for Economic Affairs and Labor, the City of Vienna,
the Austrian Business Agency and the Center for Innovation
and Technology. In the recent years over 140 life science
companies have been established in Vienna.
"The biotechnology scene in our region already employs
nearly 10,000 people many of whom specialize in red biotechnology.
Five life science universities, outstanding research institutions
such as IMP and IMBA, international corporations with headquarters
in Vienna for the Eastern and South Eastern European markets
and numerous dynamic start-up companies have combined to
make the industry a showpiece for Austrian technology policy,"
said Michaela Fritz and Eva Czernohorszky, Managing Directors
of LISA VR.
Latest news from the Viennese emerging start-up scene offer
proof of the dynamism of this young life science location.
For example, Affiris recently secured EUR 430 million from
GlaxoSmithKline for the rights to its Alzheimer's vaccines
currently under development, emerging company Intercell
is close to market with its Japanese Encephalitis Vaccine,
and Fibrex is a company worth monitoring after its positive
Phase II results for FX06, a fibrin derived peptide for
the treatment of reperfusion injury in myocardial infarction.
Vienna is home to the Research Institute for Molecular
Pathology, the Institute of Molecular Biotechnology, the
Austrian Center of Biopharmaceutical Technology, the Austrian
Breast and Colorectal Cancer Study Group and the Gregor
Mendel Institute for Molecular Plant Biology.
The University of Vienna, the Medical University of Vienna,
the University of Natural Resources and Applied Life Sciences,
the University of Veterinary Medicine and the Vienna University
of Technology represent five of the universities with a
focus on life sciences located in the capital.
Global life science players in Vienna include Baxter BioScience,
Boehringer Ingelheim Austria, Eli Lilly’s Vienna School
for Clinical Research, Sanochemia and Octapharma.
About EBD Group
EBD Group is the leading partnering firm for the global
life science industry. Since 1993, biotech, pharma and medical
device companies have leveraged EBD Group’s partnering conferences,
technology and services to identify business opportunities
and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading
corporations and international trade associations and include:
- BIO-Europe and BIO-Europe Spring®, the world's largest
stand-alone life science partnering conferences, supported
by the Biotechnology Industry Organization (BIO)
- BioPharm America™, EBD Group’s North American partnering
event
- EuroMedtech™, EBD Group’s new partnering event for the
innovative medical technology industry
- BioEquity Europe, the investor conference co-organized
with BioCentury Publications and BIO
EBD Group’s sophisticated Web-based partnering service,
partneringONE™, is used as the partnering engine at numerous
third-party events around the world. Outside of the conference
format, EBD Group’s consultants provide hands-on assistance
for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
About BIO
BIO represents more than 1,200 biotechnology companies,
academic institutions, state biotechnology centers and related
organizations across the United States and in more than
30 other nations. BIO members are involved in the research
and development of innovative healthcare, agricultural,
industrial and environmental biotechnology products. BIO
also produces the BIO International Convention, the world’s
largest gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around
the world.
Contact:
Constantine Theodoropulos
EBD Group
Phone: +1 617 292 7319
ctheodoropulos@ebdgroup.com
|
